Safety and efficacy of bone marrow-derived cells therapy on cardiomyopathy: a meta-analysis

Table 3 Subgroup analysis of stem cell therapy in LVEF

Subgroup	Follow-up	No. of studies	Mean difference	95% CI	P
Injection route
Intracoronary	3 months	6	4.96	3.42, 6.51	< 0.0001
	6 months	4	3.62	0.14, 7.11	0.04
	≥ 12 months	9	3.80	0.19, 7.40	0.04
Intramyocardial	3 months	2	2.24	− 3.25, 7.72	0.42
	6 months	4	5.29	1.94, 8.65	0.002
	≥ 12 months	3	1.15	− 1.30, 6.30	0.36
Cell type
BMSC	3 months	6	4.58	3.74, 5.43	< 0.0001
	6 months	5	5.19	3.24, 7.04	< 0.0001
	≥ 12 months	5	5.04	1.00, 9.02	0.01
BMNC	3 months	4	3.77	2.25, 5.28	< 0.0001
	6-month	3	0.28	− 2.72, 3.28	0.85
	≥ 12 months	8	2.97	1.04, 4.89	0.002
Dosage
10⁶	3 months	3	5.12	− 0.62, 10.86	0.08
	6 months	3	3.23	0.79, 5.68	0.009
	≥ 12 months	4	1.16	− 2.22, 4.54	0.50
10⁸	3 months	5	4.68	3.59, 5.77	< 0.0001
	6 months	3	6.23	4.62, 7.83	< 0.0001
	≥ 12 months	5	5.40	0.56, 6.64	0.0003

BMNC bone marrow mononuclear cells, BMSC bone mesenchymal stem cells, LVEF left ventricular ejection fraction

ISSN: 1757-6512